Pharmaceutical Executive Daily: GSK's $2 Billion Acquisition of RAPT Therapeutics

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of RAPT Therapeutics, Atkins launches a new partnership to better understand consumer mindsets around GLP-1 use, and Shionogi agrees to acquire Pfizer’s remaining stake in ViiV Healthcare.

GSK has entered a definitive $2 billion agreement to acquire RAPT Therapeutics, adding a late-stage immunology asset targeting inflammatory and immune-mediated diseases. The deal reinforces GSK’s strategy to rebuild its pipeline through targeted acquisitions focused on specialty and chronic conditions.

In the consumer health and metabolic space, Atkins has announced a partnership with reality TV star Heather Gay aimed at better understanding the motivations and challenges of GLP-1 users. The collaboration reflects growing interest from nutrition and wellness brands in supporting patients beyond pharmacotherapy as GLP-1 adoption expands.

Meanwhile, Shionogi has agreed to acquire Pfizer’s remaining shareholding in ViiV Healthcare for approximately $2 billion, consolidating full ownership of the HIV-focused joint venture. The move gives Shionogi greater strategic control over ViiV’s portfolio as competition intensifies in long-acting and next-generation HIV therapies.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.